Yichou Wei1, Chao Lin2, He Li2, Zhiying Xu1, Jieti Wang1, Ruochen Li2, Hao Liu2, Heng Zhang2, Hongyong He3, Jiejie Xu4. 1. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Room 358, Building West 7, 130 Dongan Rd, Shanghai, 200032, China. 2. Department of General Surgery, Zhongshan Hospital, Fudan University, Room 1004, Building No.1, 180 Fenglin Rd, Shanghai, 200032, China. 3. Department of General Surgery, Zhongshan Hospital, Fudan University, Room 1004, Building No.1, 180 Fenglin Rd, Shanghai, 200032, China. he.hongyong@zs-hospital.sh.cn. 4. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Room 358, Building West 7, 130 Dongan Rd, Shanghai, 200032, China. jjxufdu@fudan.edu.cn.
Abstract
BACKGROUND: Chemokine (C-X-C motif) ligand 13 (CXCL13/BLC/BCA-1) is a cytokine from C-X-C chemokine family, which is selectively chemotactic for B cells. Previous research has demonstrated that high CXCL13 expression is correlated to poor prognosis in various cancers. However, the association between CXCL13 expression and gastric cancer is still unclear. METHODS: Intratumoral CXCL13 expression was evaluated by immunohistochemistry using a semi-quantitative method (modified H-score) in a testing set of 214 and a validation set of 227 randomly selected gastric cancer patients resected in 2008 in one institution. The median value was used as the cut-off point. We performed correlative analysis of CXCL-13 expression with clinicopathological variables, Kaplan-Meier analysis for association with overall survival (OS), and multivariate modeling. RESULTS: High CXCL13 expression was associated with larger tumor diameter and shorter OS. By multivariate analysis, CXCL13 expression was associated with OS independently from clinicopathological factors. Within the T2-4 stage patients group, low CXCL13 expression was associated with longer survival, especially in the subgroup of patients (57.6%) who received adjuvant chemotherapy. CONCLUSIONS: Intratumoral CXCL13 expression appears as an independent prognostic marker for patients after gastric cancer resection. In addition, CXCL13 expression may serve as a predictive biomarker of response to postoperative adjuvant chemotherapy in these patients.
BACKGROUND: Chemokine (C-X-C motif) ligand 13 (CXCL13/BLC/BCA-1) is a cytokine from C-X-C chemokine family, which is selectively chemotactic for B cells. Previous research has demonstrated that high CXCL13 expression is correlated to poor prognosis in various cancers. However, the association between CXCL13 expression and gastric cancer is still unclear. METHODS: Intratumoral CXCL13 expression was evaluated by immunohistochemistry using a semi-quantitative method (modified H-score) in a testing set of 214 and a validation set of 227 randomly selected gastric cancerpatients resected in 2008 in one institution. The median value was used as the cut-off point. We performed correlative analysis of CXCL-13 expression with clinicopathological variables, Kaplan-Meier analysis for association with overall survival (OS), and multivariate modeling. RESULTS: High CXCL13 expression was associated with larger tumor diameter and shorter OS. By multivariate analysis, CXCL13 expression was associated with OS independently from clinicopathological factors. Within the T2-4 stage patients group, low CXCL13 expression was associated with longer survival, especially in the subgroup of patients (57.6%) who received adjuvant chemotherapy. CONCLUSIONS: Intratumoral CXCL13 expression appears as an independent prognostic marker for patients after gastric cancer resection. In addition, CXCL13 expression may serve as a predictive biomarker of response to postoperative adjuvant chemotherapy in these patients.
Authors: David Y Oh; Serena S Kwek; Siddharth S Raju; Tony Li; Elizabeth McCarthy; Eric Chow; Dvir Aran; Arielle Ilano; Chien-Chun Steven Pai; Chiara Rancan; Kathryn Allaire; Arun Burra; Yang Sun; Matthew H Spitzer; Serghei Mangul; Sima Porten; Maxwell V Meng; Terence W Friedlander; Chun Jimmie Ye; Lawrence Fong Journal: Cell Date: 2020-06-03 Impact factor: 41.582
Authors: Lauren C Peres; Mary K Townsend; Brenda M Birmann; Jose R Conejo-Garcia; Yongjoo Kim; Laura D Kubzansky; Larry I Magpantay; Otoniel Martinez-Maza; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-02-09 Impact factor: 4.254